The National Cancer Institute Laboratory of Molecular Biology seeks parties for collaborative research to co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics.
There is great interest and value in developing more sensitive and efficient agents for earlier detection of hepatocellular cancer (HCC). Glypican-3 (GPC3) is a cell surface heparin sulfate glycoprotein that is expressed on the vast majority of HCC cells. The correlation between GPC3 expression and HCC makes GPC3 an attractive candidate for studying the disease progression and treatment of HCC. The presence, progression, and treatment of HCC can potentially be monitored by tracking the level of GPC3 expression on cells. This can be accomplished using GPC3-specific monoclonal antibodies such as those NCI researchers generated for the cell surface domain of GPC3 (YP6, YP7, YP8, YP9 and YP9.1).
- Treatment of HCC as a stand-alone antibody, or as an antibody-drug conjugate (immunotoxin)
- Detection of cells that express GPC3 for monitoring HCC disease progression and treatment
- Immunostaining for tumor imaging, or ELISA and immunohistochemistry applications
- Other antibody-related research use, including immunoprecipitation, Western blot analysis, etc.
- Sub-nanomolar levels of binding affinity compared to commercially available GPC3 antibodies such as 1G12
- Able to bind to wild-type GPC3 better than the GPC3 core protein that lacks heparin sulfate
Phung Y, et al. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. [PMID: 22820551]
Ho M. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. [PMID 21942912]
Ho M and Kim H. Glypican-3: a new target for cancer immunotherapy. [PMID 21112773]
- U.S. Patent Issued: U.S. Patent Number 9409994, Issued 09 Aug 2016
- Foreign Filed: China - Patent Application 201380039993.7